전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
lvef decrease
lvef langus
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
lvef 40% to
lvef 40% kuni
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
symptomatic regardless of lvef
sümptomaatiline hoolimata lvef-ist
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
lvef = left ventricular ejection fraction
lvef = vasaku vatsakese väljutusfraktsioon
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
the majority of events were asymptomatic grade 1 or 2 decrease in lvef.
enamikel juhtudel oli tegemist vasaku vatsakese väljutusfraktsiooni (lvef) asümptomaatilise 1. või 2. raskusastme langusega.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
in clinical studies, patients had a lvef 50% at baseline.
kliinilistes uuringutes oli patsientidel ravieelne lvef 50%.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
baseline and periodic evaluation of lvef is recommended in patients at risk of cardiac dysfunction.
südame düsfunktsiooni riskiga patsientidel soovitatakse lvef määramist algtasemel ja perioodiliselt ravi ajal.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
a drop in left ventricular ejection fraction (lvef) to less than 40%
vasaku vatsakese väljutusfraktsiooni (lvef) langus alla 40
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
decreases in lvef have been reported with medicinal products that block her2 activity, including perjeta.
her2 aktiivsust blokeerivate ravimite, sh perjeta kasutamisel on kirjeldatud lvef langust.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
symptomatic lvef decreases were observed in approximately 0.1% of patients who received lapatinib monotherapy.
sümptomaatilist lvef’ i langust täheldati umbes 0, 1% lapatiniibi monoteraapiat saanud patsientidest.
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
lapatinib has been associated with reports of decreases in lvef (see section 4.8).
lapatiniibi on seostatud lvef-i langusega (vt lõik 4.8).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
dabrafenib in combination with trametinib has been reported to decrease lvef (see section 4.8).
dabrafeniibi ja trametiniibi kombinatsioonravi kasutamisel on teatatud lvef vähenemisest (vt lõik 4.8).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
decrease in lvef from baseline has been reported in patients receiving cotellic (see section 4.4).
cotellic’ut saavatel patsientidel on kirjeldatud lvef langust võrreldes ravieelsega (vt lõik 4.4).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
changes in cardiac function including decreased lvef or fatal congestive heart failure (chf) may occur during or after treatment with pixuvri.
pixuvri ravi ajal või pärast ravi võivad esineda südamefunktsiooni muutused, sh vasaku vatsakese väljutusfraktsiooni (lvef) vähenemine ja raske kongestiivne südamepuudulikkus.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
in a phase iii study comparing single-agent myocet (75 mg/m2) versus single-agent doxorubicin (75 mg/m2), 12% versus 27% of patients, respectively developed a significant decrease in lvef.
iii faasi uuringus, kus võrreldi myoceti (75 mg/m2) ja doksorubitsiini (75 mg/m2) monoteraapiaid, ilmnes oluline lvef langus vastavalt 12%-l ja 27%-l patsientidest.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질: